patient and graft survival of 92.9% and 92.4% for biopsy arm, 97.9% and 94.1% for control arm. Both of the treatment arms were standard dose tacrolimus regimen. CONCLUSIONS: Three of immunosuppressive regimens are considered to have similar effi cacy in short-term patient and graft survival in lower immunological risk renal transplant patients.
PUK6 POST RENAL TRANSPLANT PATIENT SURVIVAL AND THE COMBINED ADVERSE EFFECT OF POOR RENAL FUNCTION AND NEW ONSET DIABETES MELLITUS
McEwan P 1 , Baboolal K 2 1 CRC, Cardiff, UK; 2 Cardiff and Vale NHS Trust, Cardiff, UK OBJECTIVES: A major challenge in the fi eld of renal transplantation is to prolong patient survival. Previous studies have demonstrated that renal function at 1 year is a major determinant of long term patient survival. Furthermore, the development of new onset diabetes after transplantation identifi es patients at high risk of cardiovascular events and mortality. This study aims to quantify any additive effect of impaired renal function and elevated glucose levels at 1 year post transplant on patient mortality. METHODS: Consecutive renal transplants from a single UK transplant centre over a 10 year period were analyzed using multivariate logistic regression in SPlus 8; the risk of patient mortality was assessed after stratifi cation by renal function (measured by glomerular fi ltration rate (GFR)) and impaired fasting glucose levels. RESULTS: Data were available on 307 patients with fasting glucose and GFR measurements at 1 year post transplant. Overall 37% (n = 114) had a GFR of less than 40 mL/minute and of these, 24% (n = 27) had fasting glucose levels greater than 7 mmol/L. After adjusting for age, sex and donor factors patients with fasting glucose greater than 7 mmol/L and a GFR less than 40 mL/minute had a mortality odds ratio of 5.47 (P < 0.01) compared to those with glucose levels less than 5.6 mmol/l and a GFR greater than 40 mL/minute. CONCLUSIONS: This study demonstrates that the development of impaired fasting glucose post transplants is associated with a 35% increase risk of mortality and the development of new onset diabetes associated with a 2-fold increased risk. Our study further suggests that there is a negative synergistic effect of deteriorating renal function and progressive impaired glucose regulations on patient survival. Consequently, therapeutic strategies that could both improve GFR at one year and the incidence of diabetes might be expected to improve long term patient survival.
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PUK7 THE PHARMACY BUDGET IMPACT OF EXTENDING REIMBURSEMENT OF LANTHANUM CARBONATE TO TREATMENT OF HYPERPHOSPHATEMIA (>1.78 MMOL/L) IN PATIENTS WITH CHRONIC KIDNEY DISEASE PRE-DIALYSIS IN FRANCE AND THE UNITED KINGDOM
Campbell J 1 , Tao CY 1 , Keith MS 2 , Leahy KJ 1 , Russo L 2 1 i3 Innovus, Medford, MA, USA; 2 Shire Pharmaceuticals, Wayne, PA, USA OBJECTIVES: To examine the pharmacy budget impact (PBI) of extending reimbursement of non-calcium lanthanum carbonate (LC) to treatment of hyperphosphatemia (serum phosphorus > 1.78 mmol/L) in patients with chronic kidney disease pre-dialysis (CKD-ND) in France and the UK over fi ve years. METHODS: The treated prevalence of CKD-ND and hyperphosphatemia, and the use of pharmacologic therapies, were estimated using published literature and EU nephrologist surveys. Drug costs were estimated from published sources. Market share changes were estimated from market research. Base-case analyses assumed complete medication compliance. Annual PBI was calculated as the difference in total drug costs between scenarios with and without the reimbursement extension for LC. Alternate scenarios and deterministic sensitivity analyses were also estimated. RESULTS: A small percentage of CKD-ND patients, 14,500 (7%) and 64,600 (14.6%), are estimated as hyperphosphatemic in France and the UK, respectively. Of these patients, 81% in France versus 30% in the UK are estimated to receive phosphate binder therapy. CKD-ND market share for LC is estimated at 12% in France and 1-2% in the UK. The label extension, adding hyperphosphatemic CKD-ND patients, is estimated to increase LC use primarily at the expense of calcium-based phosphate binders. The annual PBI from the label extension is estimated to grow over Years 1-5 from 0 to c1.1 M in France; and to be <£25,000 in Years 1-5 in the UK. Results are most sensitive to LC market share changes postlabel extension. CONCLUSIONS: The number of CKD-ND patients with hyperphosphatemia (>1.78 mmol/L) eligible for LC treatment is minimal in France and the UK. Assuming complete compliance, the annual PBI after 5 years of a label extension for LC to CKD-ND patients is estimated to be c1.1 M in France and <£25,000 in the UK. Calcium is the predominant therapy in CKD-ND; however, adding LC may result in a low pharmacy budget impact.
PUK8 BUDGET IMPACT ANALYSIS OF ALISKIRENO IN TYPE 2 DIABETES PATIENTS WITH HYPERTENSION AND NEPHROPATHY IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY
García-Contreras F 1 , Nevarez A 1 , Olvera K 2 1 Mexican Institute of Social Security, Mexico, D.F., Mexico; 2 Novartis, Mexico, D.F., Mexico OBJECTIVES: To determine the budget impact of Losartan + Aliskiren versus Losartan in type 2 diabetes patients with hypertension and nephropathy in the Mexican Institute of Social Security (IMSS). METHODS: An annual budget impact analysis of the use of aliskiren in the treatment of diabetic nephropathy in the IMSS was made considering four scenarios: a) Losartan + Aliskireno; b) Losartan; c) real prevalence of diabetic nephropaty and d) estimated prevalence of diabetic nephropaty. The source of epidemiologic data was the Health National Survey (ENSA 2006) . Information source to estimate health benefi ts was AVOID study. Costing was performed through the technique of microcosting for replacement therapy with hemodialysis and peritoneal dialysis. The use of resources was the standard IMSS supportive care, costs are in 2009 USD. There was no discount rate considered due to annual temporal horizon. a probabilistic and non-probabilistic sensitivity analysis was performed. RESULTS: Aliskiren alternative prevents the use of dialysis in the real scenario of 5,946 patients, with expected savings of $ 95,461,538.46 USD, while in the estimated alternative prevents dialysis in 11.765 with expected savings of $188,846,153.85 USD. CON-CLUSIONS: Aliskiren use investment prevents up to 11,765 patients requiring dialysis with savings for the health sector of more than 188 million USD.
PUK9
REAL-LIFE DOSING OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN CHRONIC KIDNEY DISEASE (CKD)-ASSOCIATED ANEMIA: BUDGET IMPACT
Walsh CM 1 , Bilton R 1 , Robinson JE 2 1 Complete Medical Group, Macclesfi eld, UK; 2 BioTrends Research Group, Exton, PA, USA OBJECTIVES: Effective management of chronic kidney disease (CKD)-associated anaemia has been established for all erythropoiesis-stimulating agents (ESAs). The aim of this study was to establish the real-life doses and comparative costs of both shortacting ESAs and the newer longer-acting ESAs, darbepoetin alfa and the continuous erythropoietin receptor activator (C.E.R.A), and to forecast the impact of a change in current prescribing practice on health care budgets in Europe. METHODS: a retrospective chart review of CKD-associated anaemia management in 1014 pre-dialysis and 1016 dialysis patients was carried out by 261 nephrologists across the UK, Italy, Germany, Spain and France, between August 2008 and September 2009. Data collected on ESA dosing were used to populate a UK budget impact model comparing current prescribing practice with specifi c focus on C.E.R.A and darbepoetin alfa, over a fi ve-year time horizon. Data on the number of patients, ESA market shares, and unit drug costs were derived from UK sources. RESULTS: The average monthly doses of ESAs in the combined fi ve European markets (5EU) were as follows: epoetin alfa (pre-dialysis, 19,350 International Units (IU); dialysis, 35,404 IU); epoetin beta (predialysis, 18, 230 IU; dialysis, 36, 789 IU) ; darbepoetin alfa (pre-dialysis, 107 μg; dialysis, 169 μg); C.E.R.A (pre-dialysis, 98 μg; dialysis, 150 μg). The model based on UK doses showed, that after fi ve years, an increase in the use of C.E.R.A to 40% would reduce the overall ESA budget for CKD-associated anaemia by 15% compared to current prescribing practice. CONCLUSIONS: Based on real-life data, an increase in C.E.R.A prescribing may result in a cost-saving for the management of CKD-associated anaemia in the UK. This model can be applied to other European markets to forecast the local impact of a change in current prescribing practice.
